iCAD to Showcase Leading Breast Health Solutions Suite Including Expanded ProFound AI™ Platform at RSNA Annual Meeting
Company Unveils New
Initiative, ProFound AI Powered by Panorama, which will Enable Breast Imaging
Intelligence Technology to Correlate Findings Over Time
NASHUA, N.H. and Chicago – December 2, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced it will showcase its Breast Health Solutions suite including
the expanded ProFound AI™ platform in the iCAD exhibition booths (#3929 in the south
hall and #10716 in the north hall) at the Radiological Society of North America
(RSNA) Annual Meeting in Chicago, December 1-6, 2019.
iCAD’s Breast Health Solutions suite includes ProFound AI for Digital Breast Tomosynthesis (DBT), the first artificial
intelligence (AI) software for DBT to be FDA-cleared, as well as software
solutions for 2D mammography and breast density. During the meeting, the
Company will also unveil its vision for future technologies, including
solutions that will enable clinicians to more easily consider patients’ prior
images* and prospective breast cancer risk assessment over time.*
“ProFound AI has extensive potential in the realm of
clinical AI
– and in the future it will offer a more holistic clinical approach that
can provide clinicians with a broader view of each individual patient’s case,
history, and short-term risk,” said Michael Klein, Chairman and CEO of iCAD. “Today,
ProFound AI offers clinically-proven improvements in sensitivity, specificity,
time-savings and recall rates, but our panoramic vision for the future will
include innovative tools that allow physicians to correlate findings across
time and provide more tailored and personalized patient care.”
Trained with one of the largest available DBT datasets, ProFound AI rapidly and accurately analyzes
each DBT image, or slice, and provides radiologists
with key information, such as Certainty of Finding lesion and Case Scores,
which assists in clinical decision-making and improving reading efficiency. Featuring the latest in deep-learning
artificial intelligence, the algorithm allows for continuously improved
performance via ongoing updates.
Clinical data from a large reader study
involving ProFound AI for DBT were recently published in Radiology: Artificial Intelligence. According
to study findings, ProFound AI for DBT improved radiologist sensitivity by
8 percent, reduced unnecessary patient recall rates by 7.2 percent, and slashed reading time for radiologists by 52.7
percent.1Additionally, ProFound AI cut reading
time by up to 57.4 percent for radiologists reading cases of women with dense
breasts.2
Results from a subgroup analysis of this reader study
examining improvement in accuracy and reading times for traditional 2D
mammography will be presented during the meeting on Sunday, December 1 by Emily
F. Conant, M.D., professor and chief of breast imaging from the Department of
Radiology at the Perelman School of Medicine at the University of Pennsylvania
in Philadelphia. According to study findings, ProFound AI improved sensitivity
and specificity and reduced reading time for radiologists reading DBT with
digital or with synthetic 2D.
“Our reader study
demonstrated that the concurrent use of AI improved sensitivity, specificity
and reading time when reading DBT with digital or synthetic 2D images,”
according to Dr. Conant, principal investigator and lead author of the study.
“These findings show improved cancer detection benefiting our patients as well
as improved efficiency important for radiologists.
Events and clinical presentations
throughout the meeting will feature experts who can discuss clinical
perspectives and experience using ProFound AI in daily practice:
- Monday, December 2: An investor luncheon and an evening reception, “AI After Dark,” will
feature leading experts who will provide real-world experience and clinical
perspectives in breast health solutions powered by artificial intelligence. The
investor luncheon will be webcast and available online via this link. - Tuesday, December 3: Innovation Theater Presentation, “Advances in AI for personalized
breast cancer screening using image-based short-term risk assessment,” will be
presented by Mikael Eriksson, PhD, Karolinska Institutet. - Wednesday, December 4: AI Theater Presentation, “Advancements in Mammography for Cancer
Detection and Risk Prediction” will be presented by Senthil Periaswamy, PhD,
Chief Research Scientist, VP of Clinical Innovation, iCAD, Inc.
Leading experts will also be available
in the main iCAD booth (#3929 in the south hall) daily throughout the meeting
to offer live demonstrations with the technology. ProFound AI will also be
featured in major PACS company exhibits at the meeting.
ProFound AI for DBT was FDA-cleared, CE marked, and Health Canada
licensed in 2018. ProFound AI for 2D Mammography was CE marked in July 2019. For more information, visit www.icadmed.com.
*
Not yet commercially available
References:
1.)Conant, E.
et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of
Artificial Intelligence for Digital Breast Tomosynthesis.
Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096
2.)Hoffmeister,
J. (2018). Artificial Intelligence for Digital Breast Tomosynthesis – Reader
Study Results. [White paper]. Accessed via https://www.icadmed.com/assets/dmm253-reader-studies-results-rev-a.pdf
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative
cancer detection and therapy solutions. For more information, visit www.icadmed.com.
“Safe
Harbor” Statement under the Private Securities Litigation Reform Act of
1995
Certain
statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited, to the
Company’s ability to defend itself in litigation matters, to achieve business
and strategic objectives, the risks of uncertainty of patent protection, the
impact of supply and manufacturing constraints or difficulties, uncertainty of
future sales levels, protection of patents and other proprietary rights, the
impact of supply and manufacturing constraints or difficulties, product market
acceptance, possible technological obsolescence of products, increased
competition, litigation and/or government regulation, changes in Medicare or
other reimbursement policies, risks relating to our existing and future debt
obligations, competitive factors, the effects of a decline in the economy or
markets served by the Company; and other risks detailed in the Company’s
filings with the Securities and Exchange Commission. The words “believe,”
“demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Contacts:
Media inquiries:
Jessica
Burns, iCAD
+1-201-423-4492
Investor Relations:
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, +1-212-915-2568